Literature DB >> 2846464

Viral strain dependent differences in experimental Argentine hemorrhagic fever (Junin virus) infection of guinea pigs.

R H Kenyon1, D E Green, J I Maiztegui, C J Peters.   

Abstract

Guinea pigs infected with low-passage Junin virus of human origin showed viral strain dependent differences in mortality, LD50, time to death, and in viral spread and distribution. Different Junin strains appeared to cause at least two broad patterns of Argentine hemorrhagic fever in guinea pigs. A number of strains of Junin virus caused a viscerotropic type of illness in which virus replicated predominantly in lymph nodes, spleen, and bone marrow. With the most severe visceral forms of Argentine hemorrhagic fever, the guinea pigs became viremic, developed necrosis of spleen, lymph nodes, and bone marrow, showed gastric hemorrhages, and all animals died within 13-15 days. Other Junin strains induced a neurological type of illness with transient viral replication in and lymphocyte depletion of spleen and lymph nodes, with no detectable viremia or viral replication in bone marrow. Subsequently, virus was found in the brain with varying severities of polioencephalitis, and the guinea pigs frequently showed rear leg paralysis before death occurred 28-34 days after inoculation. Not all animals infected with a neurotropic strain developed all these signs. One viral strain induced some signs characteristic of both patterns of illness. Although the disease forms in the guinea pig model did not strictly correlate with those observed in the humans from which these strains were obtained, the different strains of Junin virus consistently caused very different patterns of illness in infected guinea pigs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846464     DOI: 10.1159/000150039

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  7 in total

1.  Guinea Pig Transferrin Receptor 1 Mediates Cellular Entry of Junín Virus and Other Pathogenic New World Arenaviruses.

Authors:  Brady T Hickerson; Jonna B Westover; Zhongde Wang; Young-Min Lee; Brian B Gowen
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

2.  Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs.

Authors:  Nadezhda E Yun; Nathaniel S Linde; Natallia Dziuba; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Judy F Aronson; Olga V Chumakova; Heather M Lander; Clarence J Peters; Slobodan Paessler
Journal:  Am J Trop Med Hyg       Date:  2008-08       Impact factor: 2.345

3.  Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of Low Volume Sample Analysis.

Authors:  Jillian A Condrey; Timothy Flietstra; Kaitlyn M Nestor; Elizabeth L Schlosser; JoAnn D Coleman-McCray; Sarah C Genzer; Stephen R Welch; Jessica R Spengler
Journal:  Microorganisms       Date:  2020-07-27

Review 4.  Junín virus pathogenesis and virus replication.

Authors:  Ashley Grant; Alexey Seregin; Cheng Huang; Olga Kolokoltsova; Allan Brasier; Clarence Peters; Slobodan Paessler
Journal:  Viruses       Date:  2012-10-19       Impact factor: 5.048

5.  Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.

Authors:  Brian B Gowen; Donald F Smee; Min-Hui Wong; Jeffery O Hall; Kie-Hoon Jung; Kevin W Bailey; John R Stevens; Yousuke Furuta; John D Morrey
Journal:  PLoS One       Date:  2008-11-14       Impact factor: 3.240

Review 6.  Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses.

Authors:  Joseph W Golden; Christopher D Hammerbeck; Eric M Mucker; Rebecca L Brocato
Journal:  Biomed Res Int       Date:  2015-07-21       Impact factor: 3.411

Review 7.  Treatment of Argentine hemorrhagic fever.

Authors:  Delia A Enria; Ana M Briggiler; Zaida Sánchez
Journal:  Antiviral Res       Date:  2007-11-20       Impact factor: 5.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.